RECRUITING Not applicable ClinicalTrials.gov

Evaluation of Enamel Matrix Derivative in Immediate Dental Implants in the Mandibular Molar Region

Sponsor: Mansoura University • ClinicalTrials.gov ID: NCT07727655

Registry updated: 2026-09-16

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This randomized clinical trial will evaluate the effect of using an enamel matrix derivative during immediate dental implant placement in the mandibular molar region. Patients who require extraction of a non-restorable mandibular molar and immediate implant placement will be randomly assigned to receive an implant placed with enamel matrix derivative or without enamel matrix derivative. Clinical and radiographic outcomes, including implant stability and peri-implant bone changes, will be assessed over a follow-up period of six months. The results of this study aim to determine whether the use of enamel matrix derivative improves osseointegration and healing around immediate dental implants.

Interventions

Enamel Matrix Derivative (Emdogain) (Biological)
A single application of enamel matrix derivative (EMD, commercially known as Emdogain) will be applied to the extraction socket during immediate dental implant placement in the mandibular molar region. Clinical and radiographic outcomes, including implant stability and peri-implant bone changes, will be evaluated over six months. The dental implant used is a conventional screw-type titanium implant.
Immediate Dental Implant Placement (Procedure)
Participants will receive immediate dental implant placement in the mandibular molar region without enamel matrix derivative. Clinical and radiographic outcomes, including implant stability and peri-implant bone changes, will be evaluated over six months. The dental implant used is a conventional screw-type titanium implant.

Eligibility criteria

Inclusion Criteria: 1. Patients with non-restorable mandibular molar requiring dental extraction. 2. Patient medically free from systemic diseases that absolutely contraindicate implant surgery. 3. Age range: from (18 to 45) years. 4. Adequate inter-arch relation and inter-occlusal space to accommodate the prosthetic restoration (8-12mm). 5. Extraction sockets with intact bony walls and interradicular bone. 6. Jumping gap more than 2mm. 7. Patients with good oral hygiene. 8. Patients willing to participate in the study's follow-up intervals. Exclusion Criteria: 1. Patients with any pathological lesion or aggressive periodontal disease at the planned surgical site impaired the immediate implant placement. 2. smoker patients. 3. Pregnant patients. 4. Patients with para-functional habits (bruxism and clenching)

Conditions

Tooth Loss

Locations

Faculty of Dentistry, Mansoura University - Oral and Maxillofacial Surgery Department — Al Mansurah, Dakahlia Governorate, Egypt

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment